These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 22088702)

  • 1. Re.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
    Berger RE
    J Urol; 2011 May; 185(5):1729. PubMed ID: 22088702
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
    Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
    Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
    Valley-Omar Z; Sibeko S; Anderson J; Goodier S; Werner L; Arney L; Naranbhai V; Treurnicht F; Abrahams MR; Bandawe G; Swanstrom R; Karim QA; Karim SS; Williamson C
    J Infect Dis; 2012 Jul; 206(1):35-40. PubMed ID: 22551813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reformulated tenofovir gel for use as a dual compartment microbicide.
    Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D
    J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
    Mureithi MW; Poole D; Naranbhai V; Reddy S; Mkhwanazi NP; Sibeko S; Werner L; Abdool Karim Q; Abdool Karim S; Ndung'u T; Altfeld M;
    J Acquir Immune Defic Syndr; 2012 Jun; 60(2):124-7. PubMed ID: 22362152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence in the CAPRISA 004 tenofovir gel microbicide trial.
    Mansoor LE; Abdool Karim Q; Yende-Zuma N; MacQueen KM; Baxter C; Madlala BT; Grobler A; Abdool Karim SS
    AIDS Behav; 2014 May; 18(5):811-9. PubMed ID: 24643315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
    Williams BG; Abdool Karim SS; Karim QA; Gouws E
    J Acquir Immune Defic Syndr; 2011 Oct; 58(2):207-10. PubMed ID: 21654503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
    Chopera DR; Mann JK; Mwimanzi P; Omarjee S; Kuang XT; Ndabambi N; Goodier S; Martin E; Naranbhai V; Karim SA; Karim QA; Brumme ZL; Ndung'u T; Williamson C; Brockman MA;
    PLoS One; 2013; 8(8):e71758. PubMed ID: 24015191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
    Ham AS; Ugaonkar SR; Shi L; Buckheit KW; Lakougna H; Nagaraja U; Gwozdz G; Goldman L; Kiser PF; Buckheit RW
    J Pharm Sci; 2012 Apr; 101(4):1423-35. PubMed ID: 22227864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies.
    Karim QA; Baxter C; Karim SA
    BJOG; 2014 Oct; 121 Suppl 5(0 5):53-61. PubMed ID: 25335841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral vaginal gel shows promise against HIV.
    Baleta A
    Lancet; 2010 Jul; 376(9738):320. PubMed ID: 20681062
    [No Abstract]   [Full Text] [Related]  

  • 12. Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
    Sepúlveda-Crespo D; Sánchez-Rodríguez J; Serramía MJ; Gómez R; De La Mata FJ; Jiménez JL; Muñoz-Fernández MÁ
    Nanomedicine (Lond); 2015; 10(6):899-914. PubMed ID: 25867856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efavirenz in fixed combination with tenofovir and emtricitabine. Long-term effectiveness verified in new studies].
    Wepner U
    MMW Fortschr Med; 2011 May; 153(18):20-1. PubMed ID: 21604586
    [No Abstract]   [Full Text] [Related]  

  • 14. Modeling interventions to assess HIV epidemic impact in Africa.
    Vermund SH
    J Acquir Immune Defic Syndr; 2011 Oct; 58(2):121-4. PubMed ID: 21857360
    [No Abstract]   [Full Text] [Related]  

  • 15. Diverse approaches useful for microbicide trials.
    Abdool Karim SS; Abdool Karim Q
    Nature; 2007 Sep; 449(7158):24. PubMed ID: 17805274
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
    Mansoor LE; Karim QA; Werner L; Madlala B; Ngcobo N; Cornman DH; Amico KR; Fisher J; Fisher WA; Macqueen KM; Karim SS
    AIDS Behav; 2014 May; 18(5):841-8. PubMed ID: 24633717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pre-exposure prophylaxis for HIV transmission? No, unless].
    Boeke AJ; Heijnen AM
    Ned Tijdschr Geneeskd; 2013; 157(27):A6359. PubMed ID: 23838404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
    Mansoor LE; Abdool Karim Q; Mngadi KT; Dlamini S; Montague C; Nkomonde N; Mvandaba N; Baxter C; Gengiah TN; Samsunder N; Dawood H; Grobler A; Frohlich JA; Abdool Karim SS
    Trials; 2014 Dec; 15():496. PubMed ID: 25527071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical microbicides for prevention of sexually transmitted infections.
    Obiero J; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
    MacQueen KM; Weaver MA; van Loggerenberg F; Succop S; Majola N; Taylor D; Karim QA; Karim SA
    AIDS Behav; 2014 May; 18(5):826-32. PubMed ID: 24647763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.